Delivering Science Supporting Healthcare

Myositis antibody screen

Service
Test Background

Myositis specific antibodies can be found in dermatomyositis (DM) and polymyositis (PM), idiopathic myositis, anti-synthetase syndrome and CTD overlap syndromes. These are a heterogeneous group of conditions characterised by proximal muscle weakness and non- infective inflammation of skeletal muscle. The anti-synthetase syndrome (ASS) consists of myositis, interstitial lung disease (ILD), mechanics hands, pyrexia, Raynauds and arthritis. Immune mediated necrotising myopathy (IMNM) is a subtype of myositis that presents with very high creatinine kinase (CK) and profound muscle weakness. Muscle biopsies show necrosis with limited infiltration of inflammatory cells.

The laboratory tests for a panel of myositis specific and associated antibodies by recombinant immunoblot. The current panel contains Mi-2α, Mi2b, TIF1γ, MDA5, NXP2, SAE1, Ku, PM-Scl100, PM-scl75, SRP and the anti-synthetase antibodies; Jo1 (histidyl-tRNA synthetase), PL7 (threonyl-tRNA synthetase), PL12 (alanyl-tRNA synthetase), EJ (glycyl tRNA synthetase), OJ (isoelucyl tRNA syntheatse), and the non-specific Ro52 antibody.

In ASS antibodies to Jo1, PL7 or EJ are associated with more muscle disease, and antibodies to PL7, OJ or PL12 to more severe ILD. Antibodies to SRP and HMGCoA reductase are strongly associated with IMNM. HMGCoA reductase antibodies are also associated with statin induced myositis. Antibodies to Mi2 and SAE are commonly associated with dermatomyositis with mild muscel disease.

Antibodies to TIF1γ, NXP2 and MDA5 are seen in around 50% of juvenile dermatomyositis patients and identify distinct disease subsets. In adults TIF1γ and NXP2 is found with myositis-associated cancer. MDA5 antibody in myositis or dermatomyositis is a risk factor for rapidly progressing (ILD) that can result in respiratory failure.

Pm/Scl antibodies are seen in scleroderma myositis overlap disease and Ku antibodies in CTD (SLE, Sjogren’s, Scleroderma)-myositis overlap syndromes.

McHugh, N., Tansley, S. Autoantibodies in myositis. Nat Rev Rheumatol 14, 290–302 (2018).

Clinical Indications

Suspected myositis
Muscle weakness and raised creatinine kinase
CT signs of ILD
CTD overlap syndromes

Reference Range

Negative

Sample volume
5-10 mL blood (1 mL serum)
Turnaround time
10 days
Sample & Container Required
Serum (rust top RST tube)
Notes

This test is currently awaiting UKAS accreditation due to an upgrade in kit format.

Accreditation

This test is not currently accredited

Record last updated
January 2, 2026

Sample Container

5ml RST Vacutainers (Rust top)

Search test database

Test Results

Yes, we have a Pathology User Guide

Yes. Please email your request to Imperial.nwlpcustomerservice@nhs.net

Results are communicated to clinical staff and are normally not communicated direct to patients either on telephone requests or in written report. If you need to contact us please click here to view the contact details page

Please contact the Customer Service Team Monday to Friday from 8:30am – 6:00pm on 0203 313 5353. Alternatively, see the Pathology User Guide for how to contact the relevant department. If advice is not urgent you can also email your query to Imperial.nwlpcustomerservice@nhs.net

Additional tests may be added by discussion with the relevant laboratory. The time limit for adding additional tests to a sample already received in the laboratory will depend on the type of sample and the department it was sent to.

Information on the repertoire of tests performed by pathology, including reference ranges, turnaround times and specimen requirements, can be found in the test directory.

NWLP operates UKAS accredited medical laboratories as per the references below. The current scope of accreditation for all NWLP’s laboratories can be found on the UKAS website.

UKAS accredited medical laboratory/medical diagnostic service:

  • Clinical Biochemistry No. 8673
  • Haematology and Blood Transfusion No. 8674
  • Infection & Immunity Sciences (Including Immunology, Virology, Microbiology and Histocompatibility and Immunogenetics ) No. 8659
  • Cellular Pathology (Including Histopathology, Cytology and Molecular Pathology) No. 9615

If you require copies of our certificate of accreditation and associated documentation please contact Imperial.nwlpcustomerservice@nhs.net.

UKAS requires the laboratories to be accredited for a particular repertoire/scope (ISO15189), any changes or additions to repertoire require assessment by UKAS (extension to scope).

The BD Hospital Tube GuideBD GP Tube Guide and BD Paediatric Tube Guide provide visual references to the correct tube types and collection instructions.

Home testing

INSTRUCTION SHEET FOR BLOOD SAMPLE COLLECTION 

We also have two instruction videos available (one with subtitles and one without) – please click on the links to view the videos on Google.

VIDEO ON BLOOD SAMPLE COLLECTION (without subtitles)

VIDEO ON BLOOD SAMPLE COLLECTION (with subtitles)

Our accreditations

Upholding excellence in diagnostic standards

Our laboratories are accredited by the UK Accreditation Service (UKAS) against the international standard ISO15189:2022. UKAS is the accreditation body for the UK that assesses medical laboratories.

Find out more about our accreditations on the UKAS website.

UKAS website
Man in the lab handling a sample